The Medical Imaging and Technology Alliance (MITA) PET Group has rebranded as the Radiopharmaceutical Manufacturers and Theranostics Alliance (RMTA), a division of the National Electrical Manufacturers Association (NEMA).
The new name reflects an expanded focus beyond diagnostic radiopharmaceuticals to include theranostics -- integrated diagnostic and therapeutic approaches for conditions including cancer, heart disease, and Alzheimer's disease, according to the organization. RMTA unites developers of diagnostic and therapeutic radiopharmaceuticals with manufacturers of isotopes, contrast agents, nuclear imaging technologies, and integrated theranostic platforms.
The alliance said it will work to address barriers to patient access, modernize regulatory and reimbursement frameworks, and advance policies supporting safety and quality in radiopharmaceuticals and theranostics.
